NDA 205718 · Helsinn Hlthcare
Akynzeo
Netupitant, Palonosetron Hydrochloride · Oral · Substance P/Neurokinin-1 Receptor Antagonist; Serotonin-3 Receptor Antagonist
NovelLast checked: Nov 20, 2026Latest source record: Jun 2, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Oct 10, 2014
Approved uses
1
Original approval plus efficacy supplements
Registered trials
29
12 Phase 3, 3 recruiting
FAERS reports
1,200
1,119 serious, 170 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 23, 2026.
AKYNZEO capsules is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. AKYNZEO capsules is a combination of palonosetron and netupitant: palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy. AKYNZEO for injection and AKYNZEO injection are indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. AKYNZEO for injection is a combination of palonosetron and fosnetupitant, a prodrug of netupitant: palonosetron prevents nausea and vomiting during the acute phase and fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy. Limitations of Use AKYNZEO for injection and AKYNZEO injection have not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy. AKYNZEO capsules is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. AKYNZEO for injection and AKYNZEO injection are indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Limitations of Use AKYNZEO for injection and AKYNZEO injection...
Mechanism: Netupitant is a selective antagonist of human substance P/neurokinin 1 (NK-1) receptors. Palonosetron is a 5-HT 3 receptor antagonist with a strong binding affinity for this receptor and little or no affinity for other receptors. Cancer chemotherapy may be associated with a high incidence of nausea and vomiting, particularly when certain agents, such as cisplatin, are used. 5-HT 3 receptors are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema. Chemotherapeutic agents produce nausea and vomiting by stimulating the...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 10, 2014 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination NovelLabelReviewSummary Review
1 products under this application
- AKYNZEO · NETUPITANT 300MG; PALONOSETRON HYDROCHLORIDE EQ 0.5MG BASE · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Netupitant" as an intervention, any sponsor and status, largest first.
- An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and VomitingPivotal-lookingCompleted
Helsinn Healthcare SAIndustry
NCT01339260 · 1,455 participants · Start Apr 2011 · Primary completion Nov 2012
Drug: Netupitant and Palonosetron; Palonosetron and 1 more · For: Chemotherapy-Induced Nausea and Vomiting
Sites: Anniston, Alabama; Muscle Shoals, Alabama; Hot Springs, Arkansas · 172 sites in all
- Treatment of Refractory Nausea and Vomiting in Patients With Breast CancerPivotal-lookingCompleted
University of Rochester NCORP Research BaseAcademic, hospital or other
NCT03367572 · 1,363 participants · Start Apr 19, 2018 · Primary completion Apr 13, 2024
Drug: Dexamethasone; Netupitant/Palonosetron Hydrochloride and 2 more · For: Breast Carcinoma
Sites: Honolulu, Hawaii; Decatur, Illinois; New Orleans, Louisiana · 18 sites in all
- NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC RegimensPivotal-lookingCompleted
Fudan UniversityAcademic, hospital or other
NCT06331520 · 644 participants · Start May 1, 2024 · Primary completion Aug 1, 2025
Drug: Netupitant / Palonosetron Oral Capsule [Akynzeo]; Olanzapine and 1 more · For: Chemotherapy-induced Nausea and Vomiting; Highly Emetogenic Chemotherapy
Sites: Shanghai, China
- Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer PatientsPivotal-lookingStatus unknown
VIFORFRANCEIndustry
NCT03831633 · 426 participants (planned) · Start Sep 19, 2018 · Primary completion Jul 31, 2019
Drug: Akynzeo; Standard of Care · For: Oncology
Sites: Paris, France
- Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)Pivotal-lookingCompleted
Helsinn Healthcare SAIndustry
NCT04817189 · 414 participants · Start Feb 1, 2021 · Primary completion Jul 2, 2024
Drug: NEPA (300mg netupitant/0.5mg palonosetron); Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV) and 1 more · For: Chemotherapy-induced Nausea and Vomiting
Sites: Shanghai, China; Prague, Czechia; Essen, Germany · 19 sites in all
- A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and VomitingPivotal-lookingCompleted
Helsinn Healthcare SAIndustry
NCT01376297 · 413 participants · Start Jul 2011 · Primary completion Sep 2012
Drug: Netupitant and Palonosetron; Aprepitant and 2 more · For: Chemotherapy-Induced Nausea and Vomiting
Sites: Muscle Shoals, Alabama; Burbank, California; Los Angeles, California · 75 sites in all
- A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and VomitingPivotal-lookingCompleted
Helsinn Healthcare SAIndustry
NCT02517021 · 405 participants · Start Nov 2015 · Primary completion Aug 2016
Drug: Pro-netupitant/Palonosetron; Netupitant/Palonosetron and 1 more · For: Chemotherapy-Induced Nausea and Vomiting
Sites: Santa Monica, California; Whittier, California; Grand Junction, Colorado · 74 sites in all
Helsinn Healthcare SAIndustry
NCT03403712 · 404 participants · Start Mar 16, 2018 · Primary completion Sep 19, 2018
Drug: fosnetupitant/ palonosetron; netupitant/palonosetron and 1 more · For: Chemotherapy-induced Nausea and Vomiting
Sites: Tucson, Arizona; Little Rock, Arkansas; Anaheim, California · 40 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea129
- fatigue92
- diarrhoea91
- neutropenia89
- dyspnoea75
- vomiting72
- death68
- pyrexia57
- off label use56
- febrile neutropenia52
- anaemia46
- decreased appetite46
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 9 |
| 2016 | 18 |
| 2017 | 43 |
| 2018 | 75 |
| 2019 | 152 |
| 2020 | 148 |
| 2021 | 188 |
| 2022 | 92 |
| 2023 | 78 |
| 2024 | 113 |
| 2025 | 148 |
| 2026 | 136 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Akynzeo (Fosnetupitant/Palonosetron)
2024 spending
$4.8M
Beneficiaries
1,119
4,375 claims
Per beneficiary
$4,258
$32.58 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $355,121 |
| 2021 | $228,707 |
| 2022 | $2,419,510 |
| 2023 | $4,508,722 |
| 2024 | $4,764,483 |
Part D: Akynzeo (Netupitant/Palonosetron HCl)
2024 spending
$354K
Beneficiaries
99
341 claims
Per beneficiary
$3,573
$671.27 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $296,175 |
| 2021 | $398,551 |
| 2022 | $466,394 |
| 2023 | $440,871 |
| 2024 | $353,760 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
Piechotta V, Adams A, Haque M, et al. · Cochrane Database Syst Rev 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Reduced/No Dexamethasone With Netupitant/Palonosetron and Olanzapine for ChemotherapyߛInduced Nausea/Vomiting in Highly Emetogenic Chemotherapy: Phase III Noninferiority Trial.
Meng Y, Liu Y, Lin M, et al. · J Clin Oncol 2026 · Clinical Trial, Phase III, Equivalence Trial
- Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: A subanalysis from two phase III trials.
Rugo HS, Rossi G, Rizzi G, et al. · Breast 2017 · Meta-Analysis
- The Double-Blind Placebo-Controlled Study Comparing Upfront and Subsequent Netupitant in Addition to Olanzapine-Containing Regimen for Prevention of High-Dose Cisplatin-Induced Nausea/Vomiting.
Vinayanuwattikun C, Lertanansit C, Mahaparn W, et al. · Asia Pac J Clin Oncol 2025 · Randomized Controlled Trial, Comparative Study
- Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study).
Celio L, Cortinovis D, Cogoni AA, et al. · Sci Rep 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Efficacy and safety of netupitant/palonosetron combination (NEPA) in preventing nausea and vomiting in non-Hodgkin's lymphoma patients undergoing to chemomobilization before autologous stem cell transplantation.
Di Renzo N, Musso M, Scimè R, et al. · Support Care Cancer 2022 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Helsinn Hlthcare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.